Tocilizumab has emerged as a key treatment for rheumatoid arthritis, showing efficacy, safety, and potential cardiovascular ...

Purpose: The pharmacology, pharmacokinetics, clinical efficacy, safety, and role of tocilizumab in rheumatoid arthritis (RA) are reviewed. Summary: Tocilizumab is a novel monoclonal antibody that ...

The biosimilar of IL-6 inhibitor tocilizumab, called Tyenne (formerly MSB11456), has been approved for the same indications as Roche’s brand, including rheumatoid arthritis, systemic juvenile ...

Five patients started the IL-6 inhibitor tocilizumab (Actemra). In the group initiating conventional DMARDs, 71% were on steroids alone and most of the rest were on methotrexate with steroids.

During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in ...